Skip to content
MarketScale
‹ Back to IndustriesSciences

Pore Pressure is a Changing Constant

There are forces that we deal with on a daily basis that are apparent and ever-present. There are, however, other forces that are exponentially stronger, that most of us will never notice. On this episode of the MarketScale Sciences Podcast, host Sean Heath sat down with Jakob Heller from Ikon Science and they discussed…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sean Heath · BasinDrillingGeologyHydrocarbon Migration
Share

Key takeaways

01

There are forces that we deal with on a daily basis that are apparent and ever-present.

02

There are, however, other forces that are exponentially stronger, that most of us will never notice.

03

On this episode of the MarketScale Sciences Podcast, host Sean Heath sat down with Jakob Heller from Ikon Science and they discussed…

There are forces that we deal with on a daily basis that are apparent and ever-present. There are, however, other forces that are exponentially stronger, that most of us will never notice. On this episode of the MarketScale Sciences Podcast, host Sean Heath sat down with Jakob Heller from Ikon Science and they discussed the pressure associated with accurately calculating pore pressure.

The planet we walk on every day is constantly undergoing colossal change, on an unusually large scale, beneath the surface, according to Heller.

“We’re dealing with geology here, so, it’s a huge time frame that people potentially, normally wouldn’t be able to grasp.” he said. “The sort of conventional pore pressure prediction techniques were sort of developed and are best -suited for relatively young, recently deposited rocks.”

The first inclination is to assume that these calculations are strictly a mathematical process, but that is not the case, Heller explained.

“The key thing in order to be able to predict pore pressure and understand what is happening, in terms of pore pressure,” Heller said, “is to understand the geology. You have to be a very good geologist because we need to try and understand how pore pressure has developed throughout the history of the geological basin we are working in.”

There is an added layer of personal pressure that the teams face as well, explained Heller.

“The work we do, in many cases, has some implications for people drilling wells, obviously. If we get our pore pressure prediction wrong, then that might have some serious ramifications,” he said.

Heller also presented an explanation of “hydrocarbon migration.”

“One thing that is very important in terms of pressure and understanding pressure and how it has developed through time in a geological basin, is that it imposes a big control on the migration of hydrocarbons in sedimentary basins,“ he said. “That is often the case. Especially when we’re looking at conventional reservoirs, is that hydrocarbons have migrated out of the source rock and into the reservoir, the sort of container rock, into the trap.”

For the latest news, videos, and podcasts in B2B, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

SH
Sean Heath

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

SH
Sean Heath